92 studies found for:    myeloma AND (women OR woman OR female)
Show Display Options
Rank Status Study
21 Terminated Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
Condition: Refractory Multiple Myeloma
Interventions: Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: bortezomib;   Drug: dexamethasone;   Drug: cyclophosphamide
22 Completed
Has Results
American Ginseng in Treating Patients With Fatigue Caused by Cancer
Conditions: Chronic Myeloproliferative Disorders;   Fatigue;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: American ginseng;   Other: placebo
23 Active, not recruiting Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Conditions: Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
Intervention: Drug: zoledronic acid
24 Recruiting Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study
Condition: Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation
Intervention: Drug: Bortezomib
25 Not yet recruiting A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Sotatercept;   Drug: Placebo
26 Active, not recruiting
Has Results
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: filgrastim;   Biological: sargramostim;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: melphalan;   Drug: prednisone;   Drug: thalidomide;   Procedure: peripheral blood stem cell transplantation
27 Completed ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain
Conditions: Bone Metastases;   Multiple Myeloma
Interventions: Device: ExAblate 2000;   Device: Sham
28 Recruiting Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
29 Withdrawn Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Genetic: chromosomal translocation analysis;   Genetic: cytogenetic analysis
30 Terminated Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.
Conditions: Vertebral Fracture;   Multiple Myeloma;   Osteolytic Metastases
Intervention: Device: balloon kyphoplasty
31 Recruiting Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Multiple Myeloma and Renal Disease
Conditions: Relapsed Multiple Myeloma;   End-stage Renal Disease
Intervention: Drug: Carfilzomib
32 Active, not recruiting Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Conditions: Ovarian Cancer;   Renal Cancer;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Solid Tumors;   Multiple Myeloma;   Lymphoma
Interventions: Drug: Carfilzomib 30 min IV infusion;   Drug: Carfilzomib bolus administration up to 10 min;   Drug: Carfizomib 30 min infusion plus 40 mg/week dexamethasone
33 Completed A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
Conditions: Lymphoma, Mantle-Cell;   Leukemia, Lymphocytic, Chronic, B-Cell;   Leukemia, Hairy Cell;   Waldenstrom Macroglobulinemia;   Multiple Myeloma
Intervention: Drug: ON01910 Na
34 Active, not recruiting Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013
35 Active, not recruiting Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: bortezomib
36 Active, not recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Drug: CT-011;   Biological: Dendritic Cell Fusion Vaccine
37 Completed Protein Tyrosine Kinases (PTK) in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: PTK787/ZK222584
38 Completed RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: RAD001;   Drug: lenalidomide
39 Completed CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
Conditions: Hematologic Malignancy;   AML;   ALL;   CML;   Multiple Myeloma;   NHL;   Hodgkin's Lymphoma
Intervention: Device: CD+8 T cell depletion
40 Recruiting Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Plerixafor (AMD3100);   Drug: bortezomib

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years